Outlook Therapeutics, Inc. (OTLK)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
OTLK price, last 12 months
Key stats
- Previous close
- $0.4079
- Open
- $0.4453
- Day range
- $0.3845 – $0.4472
- 52-week range
- $0.1611 – $2.54
- Volume
- 6.8M
- Avg volume (20 days)
- 3.4M
- Market cap
- $100.5M
Performance
Technicals and fundamentals
About Outlook Therapeutics, Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $100.5M